Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Body mass index, asthma, and respiratory symptoms: a population-based study.

Souza ECC, Pizzichini MMM, Dias M, Cunha MJ, Matte DL, Karloh M, Maurici R, Pizzichini E.

J Bras Pneumol. 2019 Dec 20;46(1):e20190006. doi: 10.1590/1806-3713/e20190006. eCollection 2020. English, Portuguese.

2.

Translation and cultural adaptation of the King's Brief Interstitial Lung Disease health status questionnaire for use in Brazil.

Silveira K, Steidle LJM, Matte DL, Tavares PH, Pincelli MP, Pizzichini MMM, Pizzichini E, Birringer SS, Tavares MGS.

J Bras Pneumol. 2019 Sep 16;45(5):e20180194. doi: 10.1590/1806-3713/e20180194. English, Portuguese.

3.

Prevalence and Characteristics of Asthma-Chronic Obstructive Pulmonary Disease Overlap in Routine Primary Care Practices.

Krishnan JA, Nibber A, Chisholm A, Price D, Bateman ED, Bjermer L, van Boven JFM, Brusselle G, Costello RW, Dandurand RJ, Diamant Z, Van Ganse E, Gouder C, van Kampen SC, Kaplan A, Kocks J, Miravitlles M, Niimi A, Pizzichini E, Rhee CK, Soriano JB, Vogelmeier C, Román-Rodriguez M, Carter V, D'Urzo AD, Roche N.

Ann Am Thorac Soc. 2019 Sep;16(9):1143-1150. doi: 10.1513/AnnalsATS.201809-607OC.

PMID:
31162945
4.

A review of the burden and management of mild asthma in adults - Implications for clinical practice.

Mulgirigama A, Barnes N, Fletcher M, Pedersen S, Pizzichini E, Tsiligianni I.

Respir Med. 2019 Jun;152:97-104. doi: 10.1016/j.rmed.2019.04.024. Epub 2019 May 1. Review.

PMID:
31128617
5.

Prevalence of smoking and reasons for continuing to smoke: a population-based study.

Rocha SAV, Hoepers ATC, Fröde TS, Steidle LJM, Pizzichini E, Pizzichini MMM.

J Bras Pneumol. 2019 Mar 28;45(4):e20170080. doi: 10.1590/1806-3713/e20170080. English, Portuguese.

6.

How does the GINA definition of control correlate with quality of life and sputum cellularity?

Pizzichini MMM, Rocha CC, de Souza Tavares MG, Steidle LJM, Maureci da Silva R, Dal Pizzol F, Gibson PG, Pizzichini E.

ERJ Open Res. 2019 Feb 4;5(1). pii: 00146-2018. doi: 10.1183/23120541.00146-2018. eCollection 2019 Feb.

7.

The patient profile of individuals with Alpha-1 antitrypsine gene mutations at a referral center in Brazil.

Felisbino MB, Fernandes FLA, Nucci MCNM, Pinto RMC, Pizzichini E, Cukier A.

J Bras Pneumol. 2018 Sep-Oct;44(5):383-389. doi: 10.1590/S1806-37562017000000420. English, Portuguese.

8.

Evaluation of the preference, satisfaction and correct use of Breezhaler® and Respimat® inhalers in patients with chronic obstructive pulmonary disease - INHALATOR study.

Oliveira MVC, Pizzichini E, da Costa CH, Fritscher CC, Vianna EO, Teixeira PJZ, Stirbulov R, Rabahi MF, Pinho NC.

Respir Med. 2018 Nov;144:61-67. doi: 10.1016/j.rmed.2018.10.006. Epub 2018 Oct 9.

9.

IL-5 Levels in Nasosorption and Sputosorption Correlate with Sputum Eosinophilia in Allergic Asthma.

Melo JT Jr, Tunstall T, Pizzichini MMM, Maurici R, Rocha CC, Dal-Pizzol F, Gonçalves J, Hansel TT, Thwaites RS, Pizzichini E.

Am J Respir Crit Care Med. 2019 Jan 15;199(2):240-243. doi: 10.1164/rccm.201807-1279LE. No abstract available.

10.

Rhinosinusitis symptoms, smoking and COPD: Prevalence and associations.

Caminha GP, Pizzichini E, Lubianca Neto JF, Hopkins C, Moreira JDS, Pizzichini MMM.

Clin Otolaryngol. 2018 Dec;43(6):1560-1565. doi: 10.1111/coa.13215. Epub 2018 Sep 19.

PMID:
30152142
11.

Is the COPD Assessment Test sensitive for differentiating COPD patients from active smokers and nonsmokers without lung function impairment? A population-based study.

Karloh M, Rocha SAV, Pizzichini MMM, Cavalli F, Matte DL, Pizzichini E; Respira Floripa Group.

J Bras Pneumol. 2018 May-Jun;44(3):213-219. doi: 10.1590/S1806-37562017000000149. English, Portuguese.

12.

Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials.

Martinez FJ, Rabe KF, Calverley PMA, Fabbri LM, Sethi S, Pizzichini E, McIvor A, Anzueto A, Alagappan VKT, Siddiqui S, Reisner C, Zetterstrand S, Román J, Purkayastha D, Bagul N, Rennard SI.

Am J Respir Crit Care Med. 2018 Nov 15;198(10):1268-1278. doi: 10.1164/rccm.201712-2493OC.

PMID:
29763572
13.

Translation and cultural adaptation of a specific instrument for measuring asthma control and asthma status: the Asthma Control and Communication Instrument.

Tavares MGS, Brümmer CF, Nicolau GV, Melo JT Jr, Nazário NO, Steidle LJM, Patino CM, Pizzichini MMM, Pizzichini E.

J Bras Pneumol. 2017 Jul-Aug;43(4):264-269. doi: 10.1590/S1806-37562016000000182. English, Portuguese.

14.

Rigor Is Needed When Making Comparative Analyses of Biologics in Severe Asthma.

Prazma CM, Katial R, Howarth P, Bradford E, Martin N, Pizzichini E.

Am J Respir Crit Care Med. 2018 Jun 1;197(11):1508-1510. doi: 10.1164/rccm.201712-2455LE. No abstract available.

PMID:
29360390
15.

Demographic Characteristics and Clinical Outcomes in Patients from Latin America Versus the Rest of the World: A TIOSPIR® Post-Hoc Analysis.

Anzueto A, Calverley PMA, Mueller A, Metzdorf N, Haensel M, Jardim JR, Pizzichini E, Giraldo H, Ramirez-Venegas A, Giugno ER.

Arch Bronconeumol. 2018 Mar;54(3):140-148. doi: 10.1016/j.arbres.2017.11.010. Epub 2018 Jan 6. English, Spanish.

16.

Extrafine Versus Fine Inhaled Corticosteroids in Relation to Asthma Control: A Systematic Review and Meta-Analysis of Observational Real-Life Studies.

Sonnappa S, McQueen B, Postma DS, Martin RJ, Roche N, Grigg J, Guilbert T, Gouder C, Pizzichini E, Niimi A, Phipatanakul W, Chisholm A, Dandurand RJ, Kaplan A, Israel E, Papi A, van Aalderen WMC, Usmani OS, Price DB.

J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):907-915.e7. doi: 10.1016/j.jaip.2017.07.032. Epub 2017 Sep 20.

17.

The Quebec Sleep Questionnaire on quality of life in patients with obstructive sleep apnea: translation into Portuguese and cross-cultural adaptation for use in Brazil.

Melo JT Júnior, Maurici R, Tavares MGS, Pizzichini MMM, Pizzichini E.

J Bras Pneumol. 2017 Sep-Oct;43(5):331-336. doi: 10.1590/S1806-37562016000000160. Epub 2017 Jul 31. English, Portuguese.

18.

Blood eosinophil count and exacerbation risk in patients with COPD.

Kerkhof M, Sonnappa S, Postma DS, Brusselle G, Agustí A, Anzueto A, Jones R, Papi A, Pavord I, Pizzichini E, Popov T, Roche N, Ryan D, Thomas M, Vogelmeier C, Chisholm A, Freeman D, Bafadhel M, Hillyer EV, Price DB.

Eur Respir J. 2017 Jul 20;50(1). pii: 1700761. doi: 10.1183/13993003.00761-2017. Print 2017 Jul. No abstract available.

19.

Cardiovascular risks in smokers treated with nicotine replacement therapy: a historical cohort study.

Dollerup J, Vestbo J, Murray-Thomas T, Kaplan A, Martin RJ, Pizzichini E, Pizzichini MMM, Burden A, Martin J, Price DB.

Clin Epidemiol. 2017 Apr 26;9:231-243. doi: 10.2147/CLEP.S127775. eCollection 2017.

20.

Chronic obstructive pulmonary disease exacerbation in the intensive care unit: clinical, functional and quality of life at discharge and 3 months of follow up.

Viana RCTP, Pincelli MP, Pizzichini E, Silva AP, Manes J, Marconi TD, Steidle LJM.

Rev Bras Ter Intensiva. 2017 Jan-Mar;29(1):47-54. doi: 10.5935/0103-507X.20170008. Portuguese, English.

21.

Identifying Risk of Future Asthma Attacks Using UK Medical Record Data: A Respiratory Effectiveness Group Initiative.

Blakey JD, Price DB, Pizzichini E, Popov TA, Dimitrov BD, Postma DS, Josephs LK, Kaplan A, Papi A, Kerkhof M, Hillyer EV, Chisholm A, Thomas M.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1015-1024.e8. doi: 10.1016/j.jaip.2016.11.007. Epub 2016 Dec 22.

PMID:
28017629
22.

Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.

Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Anzueto A, Alagappan VK, Siddiqui S, Rekeda L, Miller CJ, Zetterstrand S, Reisner C, Rennard SI.

Am J Respir Crit Care Med. 2016 Sep 1;194(5):559-67. doi: 10.1164/rccm.201607-1349OC.

PMID:
27585384
23.

Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.

Rennard SI, Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Siddiqui S, Anzueto A, Zhu H.

Int J Chron Obstruct Pulmon Dis. 2016 Aug 17;11:1921-8. doi: 10.2147/COPD.S109661. eCollection 2016.

24.

Prevalence of depression in COPD: A systematic review and meta-analysis of controlled studies.

Matte DL, Pizzichini MM, Hoepers AT, Diaz AP, Karloh M, Dias M, Pizzichini E.

Respir Med. 2016 Aug;117:154-61. doi: 10.1016/j.rmed.2016.06.006. Epub 2016 Jun 7. Review.

25.

Temporal trends in the prevalence of asthma and rhinoconjunctivitis in adolescents.

Wilmer FA, Maurici R, Nazário CA, Nazário KC, Pássaro PF, Piazza HE, Bertoldi RA, Pizzichini E, Pizzichini MM.

Rev Saude Publica. 2015;49. pii: S0034-89102015000100272. doi: 10.1590/S0034-8910.2015049005558. Epub 2015 Dec 31. English, Portuguese.

26.

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial.

Paggiaro P, Halpin DM, Buhl R, Engel M, Zubek VB, Blahova Z, Moroni-Zentgraf P, Pizzichini E.

J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):104-13.e2. doi: 10.1016/j.jaip.2015.08.017. Epub 2015 Nov 7.

27.

Current role of anticholinergic drugs in the treatment of asthma: key messages for clinical practice.

Pizzichini MM, Kerstjens HA, Pizzichini E.

Pol Arch Med Wewn. 2015;125(11):859-66. Epub 2015 Oct 30. Review. Erratum in: Pol Arch Med Wewn. 2015;125(12):954.

28.

The COPD Assessment Test: What Do We Know So Far?: A Systematic Review and Meta-Analysis About Clinical Outcomes Prediction and Classification of Patients Into GOLD Stages.

Karloh M, Fleig Mayer A, Maurici R, Pizzichini MMM, Jones PW, Pizzichini E.

Chest. 2016 Feb;149(2):413-425. doi: 10.1378/chest.15-1752. Epub 2016 Jan 12. Review.

PMID:
26513112
29.

Pentraxin 3 sputum levels differ in patients with chronic obstructive pulmonary disease vs asthma.

Schwingel FL, Pizzichini E, Kleveston T, Morato EF, Pinheiro JT, Steidle LJ, Dal-Pizzol F, Rocha CC, Pizzichini MM.

Ann Allergy Asthma Immunol. 2015 Dec;115(6):485-9. doi: 10.1016/j.anai.2015.10.003. Epub 2015 Oct 24.

PMID:
26508705
30.

A summary of the new GINA strategy: a roadmap to asthma control.

Reddel HK, Bateman ED, Becker A, Boulet LP, Cruz AA, Drazen JM, Haahtela T, Hurd SS, Inoue H, de Jongste JC, Lemanske RF Jr, Levy ML, O'Byrne PM, Paggiaro P, Pedersen SE, Pizzichini E, Soto-Quiroz M, Szefler SJ, Wong GW, FitzGerald JM.

Eur Respir J. 2015 Sep;46(3):622-39. doi: 10.1183/13993003.00853-2015. Epub 2015 Jul 23. Review.

31.

Author correction. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).

Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, Fležar M, Hébert J, McGarvey L, Pizzichini E, Reid J, Veale A, Grönke L, Hamilton A, Korducki L, Tetzlaff K, Waitere-Wijker S, Watz H, Bateman E.

Eur Respir J. 2015 Jun;45(6):1763. doi: 10.1183/09031936.50136014. No abstract available.

32.

Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials.

Kerstjens HA, Casale TB, Bleecker ER, Meltzer EO, Pizzichini E, Schmidt O, Engel M, Bour L, Verkleij CB, Moroni-Zentgraf P, Bateman ED.

Lancet Respir Med. 2015 May;3(5):367-76. doi: 10.1016/S2213-2600(15)00031-4. Epub 2015 Feb 12.

PMID:
25682232
33.

Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.

Timmer W, Moroni-Zentgraf P, Cornelissen P, Unseld A, Pizzichini E, Buhl R.

Respir Med. 2015 Mar;109(3):329-38. doi: 10.1016/j.rmed.2014.12.005. Epub 2014 Dec 27.

34.

Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).

Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, Fležar M, Hébert J, McGarvey L, Pizzichini E, Reid J, Veale A, Grönke L, Hamilton A, Korducki L, Tetzlaff K, Waitere-Wijker S, Watz H, Bateman E.

Eur Respir J. 2015 Apr;45(4):969-79. doi: 10.1183/09031936.00136014. Epub 2015 Jan 8. Erratum in: Eur Respir J. 2015 Jun;45(6):1763.

35.

Effects of prednisone on eosinophilic bronchitis in asthma: a systematic review and meta-analysis.

Sakae TM, Maurici R, Trevisol DJ, Pizzichini MM, Pizzichini E.

J Bras Pneumol. 2014 Oct;40(5):552-63. Review. English, Portuguese.

36.

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.

Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B, Khatry DB, van der Merwe R, Kolbeck R, Molfino NA, Raible DG.

Lancet Respir Med. 2014 Nov;2(11):879-890. doi: 10.1016/S2213-2600(14)70201-2. Epub 2014 Oct 8.

PMID:
25306557
37.

Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.

Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC, Paggiaro P.

Int J Chron Obstruct Pulmon Dis. 2014 Jul 5;9:697-714. doi: 10.2147/COPD.S62502. eCollection 2014.

38.

Reliability of a rapid hematology stain for sputum cytology.

Gonçalves J, Pizzichini E, Pizzichini MM, Steidle LJ, Rocha CC, Ferreira SC, Zimmermann CT.

J Bras Pneumol. 2014 May-Jun;40(3):250-8. English, Portuguese.

39.

Leicester Cough Questionnaire: translation to Portuguese and cross-cultural adaptation for use in Brazil.

Felisbino MB, Steidle LJ, Gonçalves-Tavares M, Pizzichini MM, Pizzichini E.

J Bras Pneumol. 2014 May-Jun;40(3):213-21. English, Portuguese.

40.

Complementing the randomized controlled trial evidence base. Evolution not revolution.

Price D, Bateman ED, Chisholm A, Papadopoulos NG, Bosnic-Anticevich S, Pizzichini E, Hillyer EV, Buist AS.

Ann Am Thorac Soc. 2014 Feb;11 Suppl 2:S92-8. doi: 10.1513/AnnalsATS.201308-276RM.

PMID:
24559027
41.

Exacerbations of COPD and symptoms of gastroesophageal reflux: a systematic review and meta-analysis.

Sakae TM, Pizzichini MM, Teixeira PJ, Silva RM, Trevisol DJ, Pizzichini E.

J Bras Pneumol. 2013 May-Jun;39(3):259-71. doi: 10.1590/S1806-37132013000300002. Review. English, Portuguese.

42.

Fluticasone/formoterol dry powder versus budesonide/formoterol in adults and adolescents with uncontrolled or partly controlled asthma.

Cukier A, Jacob CM, Rosario Filho NA, Fiterman J, Vianna EO, Hetzel JL, Neis MA, Fiss E, Castro FF, Fernandes AL, Stirbulov R, Pizzichini E; AIR Brazilian Study Group.

Respir Med. 2013 Sep;107(9):1330-8. doi: 10.1016/j.rmed.2013.06.018. Epub 2013 Jul 9.

43.

SNOT-22: psychometric properties and cross-cultural adaptation into the Portuguese language spoken in Brazil.

Caminha GP, Melo Junior JT, Hopkins C, Pizzichini E, Pizzichini MM.

Braz J Otorhinolaryngol. 2012 Dec;78(6):34-9.

44.
45.

Gastroesophageal reflux disease and airway hyperresponsiveness: concomitance beyond the realm of chance?

Ratier JC, Pizzichini E, Pizzichini M.

J Bras Pneumol. 2011 Sep-Oct;37(5):680-8. Review. English, Portuguese.

46.

Sputum induction in severe exacerbations of asthma: safety of a modified method.

Vieira MO, Pizzichini E, Steidle LJ, da Silva JK, Pizzichini MM.

Eur Respir J. 2011 Oct;38(4):979-80. doi: 10.1183/09031936.00029511. No abstract available.

47.

Cellular composition of induced sputum in healthy adults.

Veras TN, Pizzichini E, Steidle LJ, Rocha CC, Moritz P, Pizzichini MM.

J Bras Pneumol. 2011 May-Jun;37(3):348-53. English, Portuguese.

48.

The Asthma Control Scoring System: translation and cross-cultural adaptation for use in Brazil.

Tavares MG, Pizzichini MM, Steidle LJ, Nazário NO, Rocha CC, Perraro MC, Pizzichini E.

J Bras Pneumol. 2010 Nov-Dec;36(6):683-92. English, Portuguese.

49.

[Prevalence of asthma symptoms and risk factors among adolescents in Tubarão and Capivari de Baixo, Santa Catarina State, Brazil].

Breda D, Freitas PF, Pizzichini E, Agostinho FR, Pizzichini MM.

Cad Saude Publica. 2009 Nov;25(11):2497-506. Portuguese.

50.

Monitoring sputum eosinophils in mucosal inflammation and remodelling: a pilot study.

Chakir J, Loubaki L, Laviolette M, Milot J, Biardel S, Jayaram L, Pizzichini M, Pizzichini E, Hargreave FE, Nair P, Boulet LP.

Eur Respir J. 2010 Jan;35(1):48-53. doi: 10.1183/09031936.00130008. Epub 2009 Jul 16.

Supplemental Content

Loading ...
Support Center